Palvella Therapeutics Inc. (PI6 F) stock market data APIs
€85.0277
0(0%)
as of January 19, 2026
Try our APIs with
free plan!
Palvella Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Prev. Close
85.0277
Open
85.0277
High
85.0277
Low
85.0277
52 wk Range
11.8-94
Market Cap
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Palvella Therapeutics Inc. data using free add-ons & libraries
Get Palvella Therapeutics Inc. Fundamental Data
Palvella Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Palvella Therapeutics Inc. News
New
Pieris lays off most staff after AstraZeneca pulls out of partnership
Pieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale.
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
Pieris Pharmaceuticals’ PIRS shares were up almost 12% on Jul 18, after management announced strategic update in light of the recent events that have impacted its respiratory franchise. In order to ...
Why Pieris Pharmaceuticals Shares Shooting Higher Today?
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled res...
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
BOSTON,MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
